Ophthalmic Innovation
Advancing the industry’s most comprehensive ophthalmic surgical and pharmaceutical pipeline
At Glaukos, we are dedicated to addressing the greatest unmet needs of the global ophthalmic market, for physicians and for patients. That’s why we’ve spent more than a decade re-investing in R&D and clinical trial programs to develop and advance a deep pipeline of novel therapies currently being evaluated in FDA clinical trials, while leading the industry in clinical support and patient education resources. And it’s why we’re seeking to leverage our platform technologies to build an unrivaled portfolio of next-generation surgical and pharmaceutical therapies in glaucoma, corneal health, and retinal disease.
We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing.

Our Strategy for Long-Term Growth
Pipeline Currently Includes 15 Candidates, Plus Additional Undisclosed Programs
Product/Candidate | Platform/Product Type | Targeted Indication | Status | ||||||
---|---|---|---|---|---|---|---|---|---|
Product/CandidateiStent | Platform/Product TypeTrabecular Bypass Stents |
Targeted IndicationApproved |
|||||||
Product/CandidateiStent inject / iStent inject W | Platform/Product TypeTrabecular Bypass Stents |
Targeted IndicationApproved |
|||||||
Product/CandidateiStent SA | Platform/Product TypeTrabecular Bypass Stents |
Targeted IndicationPivotal IDE Trial |
|||||||
Product/CandidateiStent infinite | Platform/Product TypeTrabecular Bypass Stents |
Targeted IndicationFDA Submission |
|||||||
Product/CandidateiPRIME | Platform/Product TypeViscodelivery |
Targeted IndicationPMA non-approvable; review ongoing |
|||||||
Product/CandidatePreserFlo (Santen) | Platform/Product TypeMicroshunt |
Targeted IndicationFDA Submission |
|||||||
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 |
Product/Candidate | Platform/Product Type | Targeted Indication | Status | ||||||
---|---|---|---|---|---|---|---|---|---|
Product/CandidateiDose TR | Platform/Product TypeSustained-Release System |
Targeted IndicationPhase 3 |
|||||||
Product/CandidateiDose TREX | Platform/Product TypeSustained-Release System |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateiDose ROCK | Platform/Product TypeSustained-Release System |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateiLink® Epi-off (Photrexa) | Platform/Product TypeBio-Activated |
Targeted IndicationApproved |
|||||||
Product/CandidateiLink® Epi-on (Epioxa) | Platform/Product TypeBio-Activated |
Targeted IndicationPhase 3 |
|||||||
Product/CandidateiLink® Epi-on Next Generation | Platform/Product TypeBio-Activated |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateDry Eye Candidate | Platform/Product TypeEyelid Transdermal Platform |
Targeted IndicationPre-clinical |
|||||||
Product/CandidatePresbyopia Candidate | Platform/Product TypeEyelid Transdermal Platform |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateMulti-Kinase Inhibitor SR | Platform/Product TypeBio-Erodible |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateTriamcinolone Acetonide SR | Platform/Product TypeBio-Erodible |
Targeted IndicationPre-clinical |
|||||||
Product/CandidateAnti-VEGF SR | Platform/Product TypeBio-Erodible |
Targeted IndicationPre-clinical |
|||||||
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 |
Product/Candidate | Platform/Product Type | Targeted Indication | Status | ||||||
---|---|---|---|---|---|---|---|---|---|
Product/CandidateIOP Sensor | Platform/Product TypeImplantable sensor |
Targeted IndicationPre-clinical |
|||||||
Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | FDA Submission | Approved1 |
*2019 Glaukos fiscal year
1 In US